期刊文献+

卵巢癌患者调节性T细胞比率和肿瘤标志物CA125、CA19-9测定及临床意义 被引量:10

Detection of regulatory T cells ratio and tumor markers CA125,CA19-9 in patients with ovarian cancer and its clinical significance
下载PDF
导出
摘要 目的 探讨卵巢癌患者、卵巢良性疾病及健康成人女性调节性T细胞(Tregs)和肿瘤标志物CA125、CA19-9水平的差异,并将其与临床病理因素及预后进行相关分析。方法 选择2016年10月~2017年10月承德医学院附属医院妇科收治的经病理确诊的卵巢癌患者43例,设为恶性组,另选择同期医院收治的卵巢良性疾病患者55例作为良性组,健康体检妇女50例作为对照组。比较3组患者Tregs和肿瘤标志物CA125、CA19-9在卵巢癌患者中的表达水平,分析其与临床病理因素及预后的关系。结果 恶性组和良性组Tregs比例、CA125和CA19-9水平均高于对照组,恶性组Tregs比例、CA125和CA19-9水平高于良性组(P<0.05)。CA125、CA19-9、Tregs水平与患者的年龄差异无显著性(P>0.05);CA125水平与卵巢癌患者的淋巴结是否转移、肿瘤分期和组织学类型均有关;Tregs表达水平与卵巢癌患者的淋巴结是否转移和肿瘤分期均相关,CA19-9水平只与肿瘤分期相关(P<0.05)。随访12个月后,Tregs^(low)组中位生存时间高于Tregs^(high)组(P<0.05)。卵巢癌中Tregs数与CA125存在显著正相关性(P<0.05),而与CA19-9不具有相关性(P>0.05)。结论 Tregs、CA125和CA19-9均可有望成为卵巢癌临床诊断、治疗和预后的指标。 Objective To investigate the difference of ovarian benign diseases and healthy regulatory T cells( Tregs) and tumor markers CA125 and CA19-9 in patients with ovarian cancer,and to analyze their correlation with clinicopathological factors and prognosis. Methods We selected 43 cases pathologically diagnosed ovarian cancer patients in gynecological department from October 2016 to October 2017 in our hospital as a malignant group,another 55 cases of benign ovarian patients treated in the same period as benign group,50 cases of healthy physical examination women as control group. The Tregs number and expression levels of tumor markers CA125 and CA19-9 in ovarian cancer were compared among the three groups,and their relationship with clinicopathological factors and prognosis was analyzed.Results The proportions of Tregs in the malignant and benign groups were higher than those in the control group,and the proportions of Tregs,CA125 and CA19-9 in the malignant group were higher than that in the benign group( P < 0. 05).There are no significant difference in the proportion of Tregs,CA125 and CA19-9 levels and the age of patients. The level of CA125 was related to the lymph node metastasis,tumor stage,and histological type in patients with ovarian cancer. Tregs ratio was associated with lymph node metastasis and tumor staging in patients with ovarian cancer. The CA19-9 level was only related to tumor stage( P<0. 05). After 12 months of follow-up,the median survival time of Tregslowgroup was higher than that of Tregshighgroup( P<0. 05).There was a significant positive correlation between the number of Tregs and CA125 in ovarian cancer( P< 0. 05),but not with CA19-9( P > 0. 05). Conclusion Tregs,CA125,and CA19-9 can all be promising markers for clinical diagnosis,treatment and prognosis of ovarian cancer.
作者 崔彭华 李志艳 张玉娟 刘莉 CUI Peng-hua;LI Zhi-yan;ZHANG Yu-juan;LIU Li(Department of Gynaecology,Affiliated Hospital of Chengde Medical College,Hebei Chengde 067000,China)
出处 《解剖学报》 CAS CSCD 北大核心 2019年第6期766-770,共5页 Acta Anatomica Sinica
基金 河北省承德市科学技术研究与发展计划项目(201706A037)
关键词 卵巢癌 调节性T细胞 CA125 CA19-9 预后 流式细胞术 Ovarian cancer Regulatory T cell CA125 CA19-9 Prognosis Flow cytometry Human
  • 相关文献

参考文献10

二级参考文献78

  • 1程蓓,俞黎铭,叶大风.上皮性卵巢癌患者凝血功能测定及其临床意义[J].浙江医学,2005,27(7):490-492. 被引量:14
  • 2刘顺民,吴昌归.肺癌患者外周血CD4^+CD25^+调节性T细胞的检测及其临床意义[J].第四军医大学学报,2006,27(10):930-932. 被引量:11
  • 3田丽媛,赵亚力,韩为东.雌激素受体在卵巢癌发生发展中作用的研究进展[J].国外医学(妇产科学分册),2007,34(4):254-257. 被引量:6
  • 4Kim M, Park IY, Lim J, et al. Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer[J]. Ann Clin Lab Sci, 2006,36 ( 4 ) :455 -460.
  • 5Uno K, Homma S, Satoh T, et al. Tissue factor expression a possible determinant of thromboembolism in ovarian cancer [ J ]. Br J Cancer,2007,96 (2) :290-295.
  • 6Batschauer APB, Figueiredo CP, Bueno EC, et al. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer[ J l. Ann Oncol,2010,21:1267-1272.
  • 7Jensen T, Kierulf P, Sandset PM,et al. Fibrinogen and fibrininduce synthesis of pminilammatory cytokines fwm 1 80-1ated peripheral blood mononuclear cells [ J ]. Thrmnb Haemost, 2007,9 ( 7 ) : 822-829.
  • 8Andersen MR,Goff BA,Lowe KA,et al. Use of a symptom index, CA125, and HE4 to predict ovarian cancer[ J]. Gyneeol Oneol, 2010,116(3) :378-383.
  • 9Matsuura Y, Robertson G, Marsden DE, et al. Thromboembolic complications in patients with clear cell carcinoma of the ovary[J]. Gynecol Oncol 2007,10 ( 4 ) :406 -410.
  • 10Beer JH, Haeberli A, Vogt A, et al. Coagulation markers predict survival in cancer patients[J]- Thromb Haemost, 2009,88 ( 5 ) : 745 -749.

共引文献182

同被引文献102

引证文献10

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部